I am posting this to put this it no the right prospective..
Last week the DEA refused to reclassify marijuana
The Drug Enforcement Administration has ruled marijuana should remain classified as a dangerous drug like heroin because studies have not confirmed its medicinal value, but the agency may itself be to blame for the lack of evidence.
The DEA denied a 9-year-old petition to initiate proceedings to reschedule marijuana in late June, claiming that "marijuana has a high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision.
http://www.rawstory.com/rs/2011/07/10/dea-rules-marijuana-has-no-medicinal-value/Now let me add some Facts..
The FDA is involved in this too..
These Folks are working with a very Large Drug Company and have for years now..
GW and Otsuka Enter Into Global Cannabinoid Research Collaboration
"Over the last few years, GW has been undertaking a primary cannabinoid research program addressing a range of therapeutic areas under the direction of Professor Roger Pertwee and in collaboration with a number of other world leading cannabinoid scientists. This collaboration with Otsuka will enable GW to accelerate and expand this program in order to develop and commercialize novel cannabinoid medicines in the exciting areas of CNS and oncology."
http://www.gwpharm.com/Cannabinoid%20Research%20Collaboration.aspxSativex Enters Phase III Clinical Program In Cancer Pain
The Phase III program is being performed in conjunction with GW’s licensing partner for Sativex® in the US, Otsuka Pharmaceutical Co. Ltd. The program, which is fully funded by Otsuka, includes two Phase III randomized placebo-controlled multi-centre multinational trials as well as a long term extension study. Each Phase III trial will include approximately 370 patients and will evaluate the efficacy and safety of Sativex versus placebo over a 5 week treatment period.
The primary efficacy measure of the Phase III trials is a patient assessment of pain using a 0-10 Numeric Rating Scale (NRS), and the primary analysis is the “continuous response analysis of percent improvement from baseline” (an analysis of percent improvement in pain across the spectrum of response levels). This analysis has yielded statistically significant results in both the Phase IIa and IIb trials and has been the key efficacy parameter discussed in the product labeling of several recently approved medicines in the US for pain. The dose range employed in the studies is 3 – 10 sprays per day.
The Phase III program follows the announcement earlier this year of positive data from a Phase IIb trial. Since this time, GW and Otsuka have met with the Food & Drug Administration (FDA) at an “end of Phase II” clinical meeting to review the Phase II clinical data and the Phase III trial design. GW and Otsuka are also currently engaged in discussions with the FDA regarding other aspects of the development plan.
So with real Facts to back my point...
The DEA which is one of this Countries major Law enforcers... Lies to All in the face of Facts.. Even with the FDA working with Drug Companies and doing research for many years...
NO MEDICAL USE MY ASS....